About Capstone Therapeutics (OTCMKTS:CAPS)
Capstone Therapeutics Corp. is a biotechnology company. The Company is engaged in developing a pipeline of peptides and other molecules aimed at helping patients with under-served medical conditions. The Company entered into a joint venture, LipimetiX Development, Inc., to develop Apo E mimetic peptide molecule AEM-28 and its analogs for the treatment for Homozygous Familial Hypercholesterolemia, Acute Hypertriglyceridemic Pancreatitis, diabetic dyslipidemia and other hyperlipidemic indications. Apolipoprotein E is a 299 amino acid protein that plays a role in lipoprotein metabolism. AEM-28 is a 28 amino acid mimetic of Apo E and AEM-28 and its analogs, including AEM-28-14, a 28 amino acid mimetic of Apo E (with an aminohexanoic acid group and a phospholipid), and both contain a domain that anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance through the heparan sulfate proteoglycan receptors (Syndecan-1) in the liver.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on Assets-127.60%
Capstone Therapeutics (OTCMKTS:CAPS) Frequently Asked Questions
What is Capstone Therapeutics' stock symbol?
Capstone Therapeutics trades on the OTCMKTS under the ticker symbol "CAPS."
How were Capstone Therapeutics' earnings last quarter?
Capstone Therapeutics Corp. (OTCMKTS:CAPS) issued its quarterly earnings data on Monday, August, 14th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter. View Capstone Therapeutics' Earnings History.
When will Capstone Therapeutics make its next earnings announcement?
Who are some of Capstone Therapeutics' key competitors?
Some companies that are related to Capstone Therapeutics include Mateon Therapeutics (MATN), Strata Skin Sciences (SSKN), Roka Bioscience (ROKA), Dextera Surgical (DXTR), Lombard Medical (EVARF), NeuroMetrix (NURO), TearLab (TEAR), Tetralogic Pharmaceuticals (TLOG), Affymax (AFFY), Delcath Systems (DCTHD), BG Medicine (BGMD), M Pharmaceutical (MPHMF), Imris (IMRSQ), Echo Therapeutics (ECTE) and Sino Biopharmaceut (SBMFF).
Who are Capstone Therapeutics' key executives?
Capstone Therapeutics' management team includes the folowing people:
- John M. Holliman III, Executive Chairman of the Board, Principal Executive Officer (Age 61)
- Leslie M. Taeger, Chief Financial Officer, Senior Vice President, Principal Financial and Accounting Officer (Age 65)
- Randolph C. Steer MD. Ph.D., Consultant (Age 67)
- Fredric J. Feldman Ph.D., Director (Age 76)
- Matthew E. Lipman, Director
- Michael E. Toporek, Director
- Elwood D. Howse Jr., Independent Director (Age 75)
How do I buy Capstone Therapeutics stock?
Shares of Capstone Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Capstone Therapeutics' stock price today?
One share of Capstone Therapeutics stock can currently be purchased for approximately $0.05.
How big of a company is Capstone Therapeutics?
Capstone Therapeutics has a market capitalization of $2.72 million. Capstone Therapeutics employs 2 workers across the globe.
How can I contact Capstone Therapeutics?
Capstone Therapeutics' mailing address is 1275 W. Washington Street Suite 104, Tempe AZ, 85281. The biotechnology company can be reached via phone at 602-286-5520 or via email at [email protected]
MarketBeat Community Rating for Capstone Therapeutics (CAPS)MarketBeat's community ratings are surveys of what our community members think about Capstone Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Capstone Therapeutics (OTCMKTS:CAPS) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Capstone Therapeutics (OTCMKTS:CAPS) Earnings History and Estimates Chart
Capstone Therapeutics (OTCMKTS CAPS) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/12/2018|| || || || || || || || |
Capstone Therapeutics (OTCMKTS:CAPS) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Capstone Therapeutics (OTCMKTS:CAPS)
No dividend announcements for this company have been tracked by MarketBeat.com
Capstone Therapeutics (OTCMKTS CAPS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.40%
Capstone Therapeutics (OTCMKTS CAPS) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/5/2017||Lloyd I Miller III||Major Shareholder||Sell||100,000||$0.06||$6,000.00|| |
|7/14/2017||Value Fund L P Biotechnology||Insider||Sell||4,341,586||$0.06||$260,495.16|| |
|1/4/2017||Leslie M Taeger||CFO||Buy||50,000||$0.07||$3,500.00|| |
|12/16/2016||Lloyd I. Miller III||Major Shareholder||Sell||38,967||$0.04||$1,558.68|| |
|12/15/2016||Lloyd I Miller III||Major Shareholder||Sell||20,000||$0.04||$800.00|| |
|8/12/2016||Lloyd I Miller III||Major Shareholder||Sell||16,000||$0.06||$960.00|| |
|8/1/2016||Lloyd I Miller III||Major Shareholder||Sell||80,000||$0.06||$4,800.00|| |
|6/8/2016||Lloyd I Miller III||Major Shareholder||Sell||14,000||$0.08||$1,120.00|| |
|12/6/2013||John M Holliman III||Chairman||Buy||25,000||$0.26||$6,500.00|| |
|8/7/2013||Lloyd I Miller III||Major Shareholder||Buy||87,500||$0.23||$20,125.00|| |
|7/30/2013||Lloyd I Miller III||Major Shareholder||Buy||1,139,000||$0.20||$227,800.00|| |
|6/10/2013||Lloyd I Miller III||Major Shareholder||Buy||300,000||$0.18||$54,000.00|| |
|4/8/2013||Fredric J Feldman||Director||Buy||25,000||$0.21||$5,250.00|| |
|12/17/2012||Lloyd I Miller III||Major Shareholder||Buy||175,000||$0.16||$28,000.00|| |
|12/6/2012||Lloyd I Miller III||Major Shareholder||Buy||19,750||$0.16||$3,160.00|| |
|10/19/2012||John M Holliman III||Chairman||Buy||150,000||$0.14||$21,000.00|| |
|9/19/2012||Lloyd I Miller III||Major Shareholder||Buy||261,183||$0.16||$41,789.28|| |
|8/28/2012||Lloyd I Miller III||Major Shareholder||Buy||938,064||$0.16||$150,090.24|| |
Capstone Therapeutics (OTCMKTS CAPS) News Headlines
Capstone Therapeutics (OTCMKTS:CAPS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Capstone Therapeutics (OTCMKTS:CAPS) Income Statement, Balance Sheet and Cash Flow Statement
Capstone Therapeutics (OTCMKTS CAPS) Stock Chart for Thursday, December, 14, 2017